Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02642094
Other study ID # CTMS 15-2096
Secondary ID 1R01CA192564-01A
Status Terminated
Phase Phase 2
First received
Last updated
Start date July 2016
Est. completion date May 1, 2022

Study information

Verified date December 2023
Source The University of Texas Health Science Center at San Antonio
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens


Description:

A non-randomized, open-label, phase II, window of opportunity trial will be carried out to see if a 5-7 day rapamycin treatment can reduce malignant markers and aberrant MaSC number


Recruitment information / eligibility

Status Terminated
Enrollment 58
Est. completion date May 1, 2022
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Women with confirmed menopausal status. All patients who have NOT had a prior bilateral oophorectomy and/or are younger than age 60, will require menopausal status verified by FSH and estradiol local labs. - Women diagnosed with DCIS/LCIS, Atypical lobular hyperplasia (ALH) or ADH lesions detected by pathology - Women scheduled for mastectomy or lumpectomy after DCIS/LCIS, ALH or ADH diagnosis - Women consented to the UT Health Cancer Center MD Anderson Cancer Center tissue biorepository (HSC20070684H) - Women of child-bearing potential willing to practice 2 forms of contraception, one of which must be a barrier method until at least 30 days after the last dose of rapamycin. - Women of child-bearing potential must have a negative serum pregnancy test at time of enrollment. - Patients must be able to swallow and retain oral medication. - All patients must have given signed informed consent prior to registration on study. - Patients must have normal organ and marrow function as defined below: 1. Leukocytes = 3,000/uL 2. Absolute neutrophil count = 1,500/uL 3. Platelets = 100,000/uL 4. AST = 2.5 X ULN 5. ALT = 2.5 X ULN 6. Total bili = 1.5 X ULN or Direct bili = 1 X ULN Exclusion Criteria: - Women who are pregnant. - Women who are receiving any other concomitant treatment for their DCIS/LCIS, ALH or ADH - Women who are taking rapamycin for another diagnosis. - Women with an allergy to rapamycin or its derivatives. - Active infection requiring systemic therapy. - Patients who are taking any pills containing herbal (alternative) medicines are NOT eligible for participation. Patients must be off any such medications by the time of registration. - Immunocompromised subjects, including patients with human immunodeficiency virus - Women currently taking strong CYP3A4 inducers or inhibitors. Drugs that cannot be coadministered with rapamycin include but are not limited to: Calcium channel blockers: nicardipine, Antifungal agents: clotrimazole, fluconazole, Antibiotics: troleandomycin, Gastrointestinal prokinetic agents: cisapride, metoclopramide, Other drugs: bromocriptine, cimetidine, danazol, HIV-protease inhibitors (e.g., ritonavir, indinavir), Anticonvulsants: carbamazepine, phenobarbital, phenytoin, Antibiotics: rifapentine. The research team can provide a full list of these medications. - Patients with any of the following conditions or complications are NOT eligible for participation: 1. GI tract disease resulting in an inability to take oral medication 2. Malabsorption syndrome 3. Require IV alimentation 4. History of prior surgical procedures affecting absorption 5. Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rapamycin
Low dose of rapamycin at 2 mg/day for -5-7 days of treatment

Locations

Country Name City State
United States University of Texas Health Science Center San Antonio San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
LuZhe Sun National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Effect of Short-term Rapamycin Treatment on Biomarker Ki67 Associated With Progression to Invasive Breast Cancer Comparing biopsy tissues before the treatment with surgical samples after rapamycin treatment in the same individuals to determine percentage nuclei with positive staining for Ki67 in the CCIS lesions. Baseline to 5-7 day rapamycin plus 3-7 day washout
Primary The Effect of Short-term Rapamycin Treatment on the Frequency of Luminal Progenitor Epithelial Cells Assessment will be used to measure changes in luminal progenitor cell population between controls and treated patients. 5-7 day rapamycin treatment plus 3-7 day washout for the treatment group.
Primary The Effect of Short-term Rapamycin Treatment on Sphere Formation Efficiency of Mammary Stem Cells Measurement of difference in sphere formation efficiency (SFE) by mammary stem cells (MaSCs) in the basal myoepithelial cell population between the control and treatment groups. SFE is an in vitro method by quantifying the number of spheres formed divided by the number of cells seeded. Higher SFE indicates higher frequency of MaSCs. 5-7 day rapamycin treatment plus 3-7 day washout for the treatment group.
Primary The Effect of Short-term Rapamycin Treatment on the Frequency of Mature Luminal Epithelial Cells Measurement of Mature luminal cell populations in the treatment group compared to the control group. 5-7 day rapamycin treatment plus 3-7 day washout for the treatment group.
Primary The Effect of Short-term Rapamycin Treatment on Sphere Formation Efficiency of Luminal Progenitor Cells The measurement of sphere formation efficiency (SFE) between luminal progenitor (LP) cells from the control group and those from the treatment group. SFE is an in vitro method by quantifying the number of spheres formed divided by the number of cells seeded. Higher SFE indicates higher frequency of LP cells. 5-7 day rapamycin treatment plus 3-7 day washout for the treatment group.
See also
  Status Clinical Trial Phase
Withdrawn NCT03285607 - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Phase 1
Completed NCT02225470 - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase 3
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Completed NCT01271738 - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT01980823 - Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Early Phase 1
Completed NCT02658708 - Bright Light on Fatigue in Women Being Treated for Breast Cancer Phase 1
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Completed NCT05584644 - A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03084536 - PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery Phase 2
Terminated NCT02907918 - Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer Phase 2
Completed NCT03007979 - Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Terminated NCT02462200 - Shave Margins in Breast Conservation Therapy Phase 2
Completed NCT03592121 - Study to Investigate the Effect of AB-101 in Breast Cancer Survivors Early Phase 1
Active, not recruiting NCT04855552 - Telehealth Weight Loss Program for Breast Cancer Survivors N/A
Active, not recruiting NCT05364450 - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors N/A
Completed NCT03494400 - Aerobic Training in Treatment for Breast Cancer N/A
Terminated NCT02375048 - Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI Phase 2
Recruiting NCT02476786 - Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Phase 2